Search
  • vanya
  • 26 Jun, 2002
  • New York

Once the domain of academics and startups, grid computing is fast emerging from its narrow confines, with tech giants trying to push the concept towards the huge commercial arena.

  • kalina
  • 24 Jun, 2002
  • New York

Although biotech stocks have been badly bruised so far, some worthy options are still left. One of them is Trimeris, which will soon offer a breakthrough in the treatment of AIDS.

  • vicky
  • 17 Jun, 2002
  • New York

The semiconductor industry has become a primary victim of the latest market sell-off. But while valuations need adjustment, a continued fall could create a major buying opportunity.

  • vanya
  • 13 Jun, 2002
  • New York

Internet incubators such as CMGI and Idealab were once the shining stars of Wall Street. Where are they two years after the burst of the dot-com bubble?

  • iliana
  • 13 Jun, 2002
  • New York

Getting a boost from middle-aged career women who swear by its relaxed fits and high-quality fabrics, J.Jill has been quietly carving a vital niche for itself in the retail arena.

  • kalina
  • 12 Jun, 2002
  • New York

Even though biotech stocks have been badly battered lately, several significant regulatory decisions may be taken in the next few months that could turn the scales in their favor

  • vanya
  • 03 Jun, 2002
  • New York

Predictions of strong growth in the CRM market have led to both software behemoths and small players rushing into the arena. But, will CRM really deliver on its stated goals?

  • iliana
  • 31 May, 2002
  • New York

Online travel agents Expedia and Travelocity have recently been flying through some really turbulent times caused mainly by the invasion of airlines into the distributors' arena.

  • kalina
  • 31 May, 2002
  • New York

This year's ASCO meeting did not offer any impressive developments, for though products showed improved success at targeting tumors, most were still years away from the market.

  • vicky
  • 31 May, 2002
  • New York

The chip Intellectual Property business is set for further expansion in 2002, although growth could be a little more modest compared with the frenetic rates of the recent past.

  • kalina
  • 31 May, 2002
  • New York

Although antisense technology has disappointed investors so far, there are clear indications that Genasense will reverse this scenario and thus win the coveted blockbuster status.

  • vanya
  • 31 May, 2002
  • New York

Investment and fundraising figures draw a bleak picture of the overall private equity landscape but hopes are rising of the emergence of better opportunities in the buyout arena.

  • iliana
  • 31 May, 2002
  • New York

With surprisingly good financials, solid growth, good profitability and a favorable demographic trend, fitness-gear maker Direct Focus offers very good odds for retail investors.

  • vicky
  • 31 May, 2002
  • New York

Chip-gear makers turned in strong first quarter earnings and reported increased order activity but the industry is still far from achieving growth in 2002.